US 12,239,717 B2
Muscle targeting complexes and uses thereof for treating dystrophinopathies
Romesh R. Subramanian, Framingham, MA (US); Mohammed T. Qatanani, Waltham, MA (US); Timothy Weeden, Waltham, MA (US); Cody A. Desjardins, Waltham, MA (US); Brendan Quinn, Waltham, MA (US); and John Najim, Waltham, MA (US)
Assigned to Dyne Therapeutics, Inc., Waltham, MA (US)
Filed by Dyne Therapeutics, Inc., Waltham, MA (US)
Filed on Aug. 15, 2024, as Appl. No. 18/805,937.
Application 18/805,937 is a continuation of application No. 18/609,032, filed on Mar. 19, 2024, granted, now 12,102,687.
Application 18/609,032 is a continuation of application No. 18/495,086, filed on Oct. 26, 2023, granted, now 11,969,475.
Application 18/495,086 is a continuation in part of application No. 18/490,905, filed on Oct. 20, 2023, abandoned.
Application 18/490,905 is a continuation of application No. 18/181,795, filed on Mar. 10, 2023, granted, now 11,839,660.
Application 18/181,795 is a continuation of application No. 17/811,401, filed on Jul. 8, 2022, granted, now 11,672,872.
Application 18/495,086 is a continuation in part of application No. 18/349,631, filed on Jul. 10, 2023, granted, now 11,986,537.
Application 18/349,631 is a continuation of application No. 17/811,370, filed on Jul. 8, 2022, granted, now 11,771,776.
Application 18/495,086 is a continuation in part of application No. 18/329,781, filed on Jun. 6, 2023, granted, now 11,844,843.
Application 18/329,781 is a continuation of application No. 18/063,795, filed on Dec. 9, 2022, granted, now 11,679,161.
Application 18/063,795 is a continuation of application No. 17/811,380, filed on Jul. 8, 2022, granted, now 11,638,761.
Application 18/495,086 is a continuation in part of application No. 18/181,700, filed on Mar. 10, 2023, abandoned.
Application 18/181,700 is a continuation of application No. 17/811,424, filed on Jul. 8, 2022, granted, now 11,633,498.
Claims priority of provisional application 63/220,043, filed on Jul. 9, 2021.
Claims priority of provisional application 63/220,262, filed on Jul. 9, 2021.
Claims priority of provisional application 63/220,155, filed on Jul. 9, 2021.
Claims priority of provisional application 63/220,144, filed on Jul. 9, 2021.
Prior Publication US 2024/0398968 A1, Dec. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/00 (2006.01); A61K 47/68 (2017.01); C07K 14/47 (2006.01); C07K 16/28 (2006.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 47/6807 (2017.08) [A61K 47/6849 (2017.08); C07K 14/4707 (2013.01); C07K 16/2881 (2013.01); C12N 15/113 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3513 (2013.01)] 30 Claims
 
1. A complex comprising an anti-transferrin receptor (TfR) antibody covalently linked to at least one oligonucleotide, wherein the antibody comprises:
(i) a heavy chain comprising a heavy chain variable region (VH) and a human IgG CH1 domain and lacking a human IgG CH2 domain and CH3 domain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 101, and
(ii) a light chain comprising a light chain variable region (VL) and a human kappa light chain constant region, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 90;
wherein each oligonucleotide is covalently linked to a lysine residue of the anti-TfR antibody, and wherein the oligonucleotide induces dystrophin exon 53 skipping.